Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/30254
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Özdemir, Z. | - |
dc.contributor.author | Başak-Türkmen, N. | - |
dc.contributor.author | Ayhan, İ. | - |
dc.contributor.author | Çiftçi, Osman | - |
dc.contributor.author | Uysal, M. | - |
dc.date.accessioned | 2020-06-08T12:12:02Z | |
dc.date.available | 2020-06-08T12:12:02Z | |
dc.date.issued | 2019 | - |
dc.identifier.issn | 0091-150X | - |
dc.identifier.uri | https://hdl.handle.net/11499/30254 | - |
dc.identifier.uri | https://doi.org/10.1007/s11094-019-01927-y | - |
dc.description.abstract | In this study, seven new 3(2H)-pyridazinone derivatives expected to show cytotoxic activity in liver and colon cancer cell lines were synthesized. Their structures were confirmed by the IR, 1 H-NMR, 13 C-NMR spectra and elementary analyses. Compunds V 1 -V 7 were tested on HEP3B (liver cancer) and HTC116 (colon cancer) cell lines for cytotoxicity by using MTS [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)- 2H-tetrazolium] proliferation assay. Human fibroblast cells were used as safety control in these tests. 6-[4-(2-Fluorophenyl)piperazine-1-yl]-3(2H)-pyridazinone-2-acetyl-2-(2-chlorobenzal)hydrazone (compound V 3 ) was the most active agent with respect to HEP3B and HTC116 cell lines. © 2019, Springer Science+Business Media, LLC, part of Springer Nature. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Springer New York LLC | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | colon cancer | en_US |
dc.subject | cytotoxicity | en_US |
dc.subject | liver cancer | en_US |
dc.subject | pyridazinone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (2 chlorobenzal)hydrazone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (2 methoxybenzal)hydrazone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (4 bromobenzal)hydrazon | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (4 chlorobenzal)hydrazone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (4 dimethylaminobenzal)hydrazone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 (4 methylbenzal)hydrazone | en_US |
dc.subject | 6 [4 (2 fluorophenyl)piperazine 1 yl] 3 (2h) pyridazinone 2 acetyl 2 benzalhydrazone | en_US |
dc.subject | cytotoxic agent | en_US |
dc.subject | hydrazone derivative | en_US |
dc.subject | piperazine derivative | en_US |
dc.subject | pyridazinone derivative | en_US |
dc.subject | unclassified drug | en_US |
dc.subject | antiproliferative activity | en_US |
dc.subject | Article | en_US |
dc.subject | carbon nuclear magnetic resonance | en_US |
dc.subject | cell viability | en_US |
dc.subject | chemical structure | en_US |
dc.subject | drug cytotoxicity | en_US |
dc.subject | drug synthesis | en_US |
dc.subject | fibroblast | en_US |
dc.subject | human | en_US |
dc.subject | human cell | en_US |
dc.subject | IC50 | en_US |
dc.subject | liquid chromatography-mass spectrometry | en_US |
dc.subject | melting point | en_US |
dc.subject | MTS assay | en_US |
dc.subject | polymerization | en_US |
dc.subject | proton nuclear magnetic resonance | en_US |
dc.title | Synthesis of new 6-[4-(2-fluorophenylpiperazine-1-YL)]-3(2H)-pyridazinone-2-acethyl-2- (substitutedbenzal)hydrazone derivatives and evulation of their cytotoxic effects in liver and colon cancer cell lines | en_US |
dc.type | Article | en_US |
dc.identifier.volume | 52 | en_US |
dc.identifier.issue | 11 | en_US |
dc.identifier.startpage | 923 | |
dc.identifier.startpage | 923 | en_US |
dc.identifier.endpage | 929 | en_US |
dc.identifier.doi | 10.1007/s11094-019-01927-y | - |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.scopus | 2-s2.0-85061507978 | en_US |
dc.identifier.wos | WOS:000461018000008 | en_US |
dc.identifier.scopusquality | Q4 | - |
dc.owner | Pamukkale University | - |
item.languageiso639-1 | en | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.openairetype | Article | - |
item.grantfulltext | none | - |
crisitem.author.dept | 14.02. Internal Medicine | - |
Appears in Collections: | Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
CORE Recommender
SCOPUSTM
Citations
8
checked on Nov 16, 2024
WEB OF SCIENCETM
Citations
8
checked on Nov 21, 2024
Page view(s)
44
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.